Evaluation of the analgesic effects of duloxetine in burn patients

Phase 3

• Conditions: Burn.; Burns and corrosions of external body surface, specified by site; T20-T25

• Registration Number: IRCT2017051422637N4
• Lead Sponsor: Vice chancellor for research, Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Burn patients requiring hospitalization for at least one week

Exclusion criteria: Bipolar mood disorder; consuming monoamine oxidase inhibitor drugs, three cyclic antidepressant drugs, tramadol, buspirone, triptan drugs, lithium, ondansetron, potent inhibitors of cytochrome P450 (CYP450) 2D6 and CYP450 1A2; creatinine clearance less than 30 ml per minute; hepatic failure; uncontrolled epilepsy; thrombocytopenia

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of pain. Timepoint: At baseline and every other day. Method of measurement: Visual Analog Scale.;Severity and quality of pain. Timepoint: At baseline and every other day. Method of measurement: Neuropathic Pain Scale.

Secondary Outcome Measures

Name	Time	Method
Dose of other analgesic drugs. Timepoint: At the end of the study. Method of measurement: Recording the dose of other analgesics.;Adverse effects. Timepoint: During the study. Method of measurement: Patient report.